Sharps Technology (NASDAQ:STSS) stock is rocketing higher on Tuesday after the company announced a potential five-year purchase agreement with Nephron. This agreement has Nephron making Sharps Technology its exclusive pre-filled copolymer syringe manufacturer. That will see it purchase a minimum of $188.5 million of syringes over those five years. The purchase agreement also includes an amendment to the cash consideration between the two companies. That includes $35 million payable in cash on closing. $1 mi ...